IMMP
Immutep and Monash University Receive Grant Funding for LAG-3 Project
Sunday, August 30, 2020 BiopharmaWatch Research 1 min read Key Takeaway: Immutep and Monash University Receive Grant Funding for LAG-3 Project
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+76%
120-day peak, hindsight
Typical move
5.4%
average across 13 past catalysts
Lead asset
eftilagimod alfa
Phase 3 · Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
Full Press Release Details
Immutep and Monash University Receive Grant Funding for LAG-3 Project.